Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations-Reference-Cited by-同舟云学术

Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations

Published:2024-06 Issue: Volume:127 Page:102751
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Rached Layal^ORCID,Laparra Ariane,Sakkal Madona,Danlos François-Xavier,Barlesi Fabrice,Carbonnel Franck,De Martin Eleonora,Ducreux Michel,Even Caroline,Le Pavec Jerome,Michot Jean-Marie,M. Ribeiro Joana,Scotte Florian,Ponce Aix Santiago,Lambotte Olivier,Baldini Capucine,Champiat Stéphane

Publisher

Elsevier BV

Reference36 articles.

1. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade;Hirsch;Br J Cancer,2019

2. Primary, adaptive, and acquired resistance to cancer immunotherapy;Sharma;Cell,2017

3. Trends in clinical development for PD-1/PD-L1 inhibitors;Xin;Nat Rev Drug Discov,2019

4. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death;Casares;J Exp Med,2005

5. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies;Patel;Immunity,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer;ESMO Real World Data and Digital Oncology;2024-09

2. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions;Bioconjugate Chemistry;2024-07-11

3. Two Cases of Cytomegalovirus Colitis During the Treatment of Immune Checkpoint Inhibitor-Associated Colitis;Cureus;2024-06-27

4. Copper-Imidazopyridines Activate P53 and Cause Apoptosis in A549 Lung Cancer Cells;2024